Ethylenediaminetetraacetic acid

Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning.

Retrieved on: 
Thursday, August 10, 2023
Other Health, Men, General Health, Pharmaceutical, Family, Consumer, Hospitals, Children, Other Consumer, Women, FDA, Health, Hepatitis, Lead poisoning, Urine, Cerebral edema, Lead, Stock, CMO, CDO, Medication, Patient, Mortality, Intracranial pressure, Anuria, Pharmaceutical industry, Ethylenediaminetetraacetic acid

Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings Inc., announced the approval, launch and immediate commercial availability of Edetate calcium disodium injection.

Key Points: 
  • Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings Inc., announced the approval, launch and immediate commercial availability of Edetate calcium disodium injection.
  • This launch will address a critical commercial shortage of this important therapy in the United States.
  • Rising’s Edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
  • “The approval and launch of Rising’s Edetate calcium disodium injection opens access to a critical treatment option for patients exposed to lead poisoning, and further demonstrates Rising’s commitment to addressing product supply shortages for the patients who need them,” said Ira Baeringer, Chief Operating Officer, Rising Pharmaceuticals.

Press release Biocartis Group NV: Biocartis Announces Nine Idylla™ Studies to be Published at Upcoming AMP 2022 Annual Meeting

Retrieved on: 
Monday, October 31, 2022
PCR, EDTA, Polymerase, Time, Research, Structured Product Labeling, Nature, Sale, Forward-looking statement, Euronext, Patient, Ethylenediaminetetraacetic acid, Lung, Industry, U.S. Securities and Exchange Commission, RSV, Polymerase chain reaction, Company, RNA, BRAF, MSI, Growth, Technology, Sepsis, EGFR, COVID-19, Person, KRAS, Melanoma, Medical device

Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19, Flu, RSV and sepsis.

Key Points: 
  • Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19, Flu, RSV and sepsis.
  • For more information, visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn.
  • This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

Retrieved on: 
Thursday, January 6, 2022
Smear layer, Disinfectant, Chromium, Outline of health sciences, Dentist, Root cap, Twitter, NASDAQ, Medicine, FDA, Technology, OEM, Workflow, Dr. NTR University of Health Sciences, Ethylenediaminetetraacetic acid, Journal of Endodontics, Bacteria, Impact, Facebook, Sodium hypochlorite, Dental care, Root canal treatment, Patient, Dentistry, Yttrium, Laser, CEO, Instagram, Cleanliness, Industry, Endodontics, DDS, BIOL, JADA, LinkedIn, Morphology, EDTA, Solution, Multimedia, Medical device, Antibiotics, Permeability, Scandium, Erbium

"This clearance enables endodontists to access state-of-the-art technology that has the potential to improve clinical outcomes and patient experiences.

Key Points: 
  • "This clearance enables endodontists to access state-of-the-art technology that has the potential to improve clinical outcomes and patient experiences.
  • "We're very pleased to complete our first OEM project, receive FDA 510(k) clearance, and deliver EdgePro units to EdgeEndo in only 12 months," adds BIOLASE President and CEO John Beaver.
  • To learn more about the new EdgePRO Laser-Assisted Microfluidic Irrigation Device EdgePro, visit edgeproendo.com To learn more about the benefits of Waterlase technology in endodontics, visit biolase.com/betterendo .
  • BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Retrieved on: 
Thursday, June 3, 2021
Chemistry, Enzymes, Acetic acids, Physical sciences, Transcription factors, Hypoxia-inducible factor, Vadadustat, Procollagen-proline dioxygenase, European Renal Association – European Dialysis and Transplant Association, Hydroxylation, Hypoxia in fish, Ethylenediaminetetraacetic acid

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .

Key Points: 
  • For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

EDTA Releases EV Leadership Plan, Praises COVID Relief Bill

Retrieved on: 
Tuesday, December 22, 2020
Amines, Antidotes, Ethylenediaminetetraacetic acid, Preservatives, Chemistry, Physical sciences, Chemical substances

EDTA President Genevieve Cullen said, The relief package includes essential relief for people and businesses in need and it contains important policy measures that will strengthen the U.S. electric drive industry at a critical time.

Key Points: 
  • EDTA President Genevieve Cullen said, The relief package includes essential relief for people and businesses in need and it contains important policy measures that will strengthen the U.S. electric drive industry at a critical time.
  • Cullen continued, Our EV Leadership Plan provides the policy blueprint to ensure U.S. leadership in electrified transportation technologies for the next century.
  • EDTA strongly supports the incoming Administrations commitment to U.S. leadership in electrification and the associations roadmap details how it can be achieved.
  • EDTA looks forward to working with all the supporters of U.S. leadership to build the future of mobility.

Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components

Retrieved on: 
Monday, November 30, 2020
Branches of biology, Microbiology, Medical specialties, Bacteriology, Gram-positive bacteria, Pathogenic bacteria, Healthcare-associated infections, Bacterial diseases, Staphylococcus aureus, Ethylenediaminetetraacetic acid, Biofilm, Staphylococcus

There were two strains of Staphylococcus aureus used for the inocula and two samples of each strain were tested as four reference groups.

Key Points: 
  • There were two strains of Staphylococcus aureus used for the inocula and two samples of each strain were tested as four reference groups.
  • The test solutions were examined following incubation for the following three time points: 60 minutes; 90 minutes; and 120 minutes.
  • For all exposure times, the number of CFU/Disk was always lower in the MLT treated disks compared to the EDTA/ethanol treated disks.
  • The researchers concluded that " taken together, the results suggest that MLT can eradicate the biofilm quicker than EDTA/ethanol."

Blood Collection Market Research Report by Product, by End-User, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Monday, November 2, 2020
Blood, Medicine, Transfusion medicine, Articles, Blood donation, Medical equipment, Drug paraphernalia, Syringe, Blood bank, Blood donation restrictions on men who have sex with men, Ethylenediaminetetraacetic acid

Blood Collection Market Research Report by Product (Blood Bags, Blood Collection Needles and Syringes, Blood Collection Tubes, Blood Lancets, and EDTA Tubes), by End-User (Blood Banks, Diagnostic Centers, and Hospitals), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

Key Points: 
  • Blood Collection Market Research Report by Product (Blood Bags, Blood Collection Needles and Syringes, Blood Collection Tubes, Blood Lancets, and EDTA Tubes), by End-User (Blood Banks, Diagnostic Centers, and Hospitals), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
    This research report categorizes the Blood Collection to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the Blood Collection Market studied across Blood Bags, Blood Collection Needles and Syringes, Blood Collection Tubes, Blood Lancets, EDTA Tubes, and Vials.
  • What is the market size and forecast of the Global Blood Collection Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Blood Collection Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Blood Collection Market?

Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®

Retrieved on: 
Tuesday, September 22, 2020
Chemistry, Physical sciences, Natural sciences, Chelating agents, Chelation, Coordination chemistry, Equilibrium chemistry, Ethylenediaminetetraacetic acid, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Mino, Heparin

Citius has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, which will be filed in the planned New Drug Application (NDA).

Key Points: 
  • Citius has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, which will be filed in the planned New Drug Application (NDA).
  • Citius has placed all registration lots on stability at the appropriate ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) conditions to support the NDA filing.
  • Citius has also developed a new exclusive synthesis process for disodium edetate ("EDTA"), a chelating agent which supplants heparin as the anti-clotting agent in Mino-Lok.
  • Mino-Lok is unique in many ways, this being one of them," said Myron Holubiak, Chief Executive Officer of Citius.

Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020

Retrieved on: 
Friday, June 5, 2020
Information and communications technology, Telecommunications, Articles, Broadcasting, Internet radio, Internet television, Webcast, European Renal Association – European Dialysis and Transplant Association, Internet, Ethylenediaminetetraacetic acid

The Company also announces its participation at the 57th ERA-EDTA Virtual Congress on June 9, 2020 with further details outlined below.

Key Points: 
  • The Company also announces its participation at the 57th ERA-EDTA Virtual Congress on June 9, 2020 with further details outlined below.
  • For those wishing to join the June 10th Corporate Update Conference Call and Webcast, the event will start promptly at 9 am MT/11 am ET.
  • It is highly recommended to access the webcast over the Internet using the following LINK .
  • A replay of the webcast (using the same LINK provided) will be available for one month following the conclusion of the event.

LawnStar Makes EDTA Chelated Nutrients a Thing of the Past for Homeowners

Retrieved on: 
Thursday, April 16, 2020
Chemistry, Physical sciences, Natural sciences, Chelating agents, Amines, Acetic acids, Antidotes, Preservatives, Chelation, Ethylenediaminetetraacetic acid, Iron(III) phosphate, Soil

Yesterday, they announced the completion of a successful transition away from using EDTA and other traditional chelating agents, across their entire liquid plant nutrition line.

Key Points: 
  • Yesterday, they announced the completion of a successful transition away from using EDTA and other traditional chelating agents, across their entire liquid plant nutrition line.
  • Now, homeowners that value a lush lawn have a new alternative," said Luke Baldacchino, President.
  • LawnStarSugar Chelated Liquid Iron is stable up to 9.5pH, meaning it is suitable for even extreme levels of soil alkalinity.
  • About LawnStar:LawnStar manufactures easy-to-use liquid lawn care solutionsfocused on bringing consumers safer, greener, more reliable plant health products at afair price.